AstraZeneca PLC (ETR:ZEG)
146.50
+0.70 (0.48%)
Nov 7, 2025, 5:35 PM CET
AstraZeneca Revenue
AstraZeneca had revenue of $15.19B USD in the quarter ending September 30, 2025, with 11.99% growth. This brings the company's revenue in the last twelve months to $58.13B, up 13.52% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$58.13B
Revenue Growth
+13.52%
P/S Ratio
4.59
Revenue / Employee
$616.41K
Employees
94,300
Market Cap
227.45B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 46.17B |
| Siemens Healthineers AG | 23.38B |
| Fresenius SE & Co. KGaA | 22.45B |
| Merck KGaA | 21.22B |
| Fresenius Medical Care AG | 19.64B |
| Sartorius Aktiengesellschaft | 3.52B |
| Redcare Pharmacy NV | 2.82B |
| Fielmann Group AG | 2.42B |
AstraZeneca News
- 1 day ago - AstraZeneca PLC 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 2 days ago - AstraZeneca (AZN) Warns UK on Drug Spending Risks - GuruFocus
- 2 days ago - AstraZeneca (AZN) Reports Positive Phase III Trial Results for Fasenra - GuruFocus
- 2 days ago - Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease - Wallstreet:Online
- 2 days ago - Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show FASENRA delayed time to first flare or worsening of disease - Business Wire
- 2 days ago - Company News for Nov 7, 2025 - Nasdaq
- 3 days ago - Why AstraZeneca Stock Topped the Market on Thursday - The Motley Fool
- 3 days ago - AstraZeneca PLC (AZN) Q3 2025 Earnings Call Transcript - Seeking Alpha